<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25853" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nevirapine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Nabila</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hoang</given-names>
          </name>
          <aff>NOVA Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nabila Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hoang Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25853.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nevirapine is a drug used in the management and treatment of HIV. It is in the NNRTI class of medications and is utilized in conjunction with other antiretroviral therapy (ART) medications. The rationale behind administering more than one medication is to decrease the chances of the virus developing a resistance to the treatment and making it ineffective. This activity outlines nevirapine's indications, actions, and contraindications as a valuable agent in managing HIV and other disorders when applicable.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for administering nevirapine.</p></list-item><list-item><p>Describe the potential adverse effects of nevirapine.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving therapy with nevirapine.</p></list-item><list-item><p>Outline some interprofessional team strategies for improving care coordination and communication to advance nevirapine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25853">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25853.s2" sec-type="Indications">
        <title>Indications</title>
        <p>First introduced into the market in the early 1990s, nevirapine is an FDA-approved medication and plays a role in treating human immunodeficiency virus (HIV) in patients, particularly HIV-1. Classified as an NNRTI or non-nucleoside reverse transcriptase inhibitor, this medication is utilized in conjunction with other antiretroviral therapy (ART) medications. When prescribed, nevirapine is a component in combination therapy with two nucleoside reverse transcriptase inhibitors (NRTI) such as zidovudine, lamivudine, abacavir, etc. The rationale behind administering more than one medication is to decrease the chances of the virus developing a resistance to the treatment and making it ineffective.<xref ref-type="bibr" rid="article-25853.r1">[1]</xref><xref ref-type="bibr" rid="article-25853.r2">[2]</xref></p>
        <p>Outside of its primary use as a medication to treat HIV, recent studies have also found that nevirapine may be able to function as a medication for diseases other than those for which it was initially intended. One such example of this is in the case of thyroid cancer. In a recently conducted experimental study, thyroid cancer cells of a human differentiated cell line received treatment with nevirapine, and the results showed that post-treatment, there was significant repression of both cell migration and invasion.<xref ref-type="bibr" rid="article-25853.r3">[3]</xref><xref ref-type="bibr" rid="article-25853.r4">[4]</xref></p>
      </sec>
      <sec id="article-25853.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The primary mechanism by which non-nucleoside reverse transcriptase inhibitors such as nevirapine function is&#x000a0;by binding to the reverse transcriptases, which are unique to HIV. The binding of the nevirapine causes the formation of a hydrophobic pocket near the active site of the reverse transcriptase. This new pocket causes an alteration in the three-dimensional configuration of the substrate-binding site, which ultimately leads to hindering HIV DNA synthesis. An important point to note is that while nevirapine is effective against HIV-1, it is not effective against HIV-2 since it is non-competitive as an inhibitor.<xref ref-type="bibr" rid="article-25853.r5">[5]</xref></p>
        <p>Nevirapine undergoes extensive hepatic metabolism; it is a CYP2B6 and 3A substrate. It is excreted in the urine (approximately 80%) and the feces (approximately 10%) and has a half-life of 25 to 30 hours.</p>
      </sec>
      <sec id="article-25853.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Adult patients: this medication is administered orally and has a variable dosage depending on the length of time of the drug's administration. During the initial 14 days of the administration, the dosage is 200 mg tablet once daily. For every day following the first 14 days, the dosage is 200 mg tablet twice daily. This medication is given in combination with other antiretroviral drugs.</p>
        <p>Pediatric patients: this medication is administered orally in liquid form and has a variable dosage depending on how long the medication has been administered. During the initial 14 days of administering the drug, the dosage is 150 mg/m once daily. For every day following the first 14 days, the dosage is 150 mg/m twice daily.</p>
        <p>There is no need for dose adjustment in renal impairment. In hemodialysis patients, no adjustment is necessary, but a 200 mg IR supplement should be administered following dialysis.<xref ref-type="bibr" rid="article-25853.r6">[6]</xref> For patients with hepatic impairment, see the Contraindications section.</p>
      </sec>
      <sec id="article-25853.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Among&#x000a0;the most well-known side effects of taking this medication is the damage it can cause to the liver.<xref ref-type="bibr" rid="article-25853.r7">[7]</xref></p>
        <p>Serious reactions also include Stevens-Johnson syndrome, anaphylaxis, toxic epidermal necrolysis, severe stomatitis, and autoimmune conditions.</p>
        <p>Other common side effects/reactions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Jaundice</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Joint ache</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Blisters</p>
          </list-item>
          <list-item>
            <p>Lipodystrophy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25853.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Decreased Liver Function, Hepatomegaly, and Cirrhosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nevirapine is contraindicated in&#x000a0;patients with Child-Pugh Class B or C liver impairment because&#x000a0;of its potential hepatotoxic effects. If the liver is already damaged or has decreased function, administration of nevirapine could lead to liver failure.</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In treatment-naive patients, nevirapine should be avoided during pregnancy, although there is no known risk of fetal harm based on human data and animal studies.</p>
          </list-item>
          <list-item>
            <p>For virologically suppressed, treatment-experienced patients, nevirapine therapy may continue during pregnancy if baseline CD4 counts are above 250.</p>
          </list-item>
          <list-item>
            <p>Pregnant patients should be enrolled in the Antiretroviral Pregnancy Registry.</p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nevirapine is contraindicated for concomitant administration with atazanavir.</p>
          </list-item>
          <list-item>
            <p>Many other agents that also affect or are metabolized by the hepatic CYP450 system&#x000a0;will require caution or dose adjustments and, in some cases, changes in therapy.<xref ref-type="bibr" rid="article-25853.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25853.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Routine examination of serum nevirapine levels in patients on this medication is crucial because different levels of nevirapine present indicate the medication&#x02019;s effectiveness, or lack thereof, in suppressing the targeted viral infection. Previously conducted clinical research has found that a plasma trough concentration of nevirapine greater than 4000 ng/mL correlates highly with the medication&#x02019;s ability to suppress the viral load of HIV such that it is undetectable. A plasma trough concentration of nevirapine less than 3000 ng/mL strongly correlates with the probability of virologic failure in patients receiving ART involving nevirapine.<xref ref-type="bibr" rid="article-25853.r9">[9]</xref></p>
        <p>It is also critical to conduct routine checks of liver function in patients treated with nevirapine, as it is known to have potentially severe hepatotoxic side effects.<xref ref-type="bibr" rid="article-25853.r10">[10]</xref>&#x000a0;In adult patients, LFTs should be checked at baseline, then 2 to 8 weeks following treatment initiation or changes, then every 3 to 6 months. In pediatric patients, LFTs should be taken at baseline, then every two weeks for four weeks, then every three months</p>
        <p>Beyond monitoring nevirapine singularly, it is essential to understand its pharmacokinetic interaction with enzymes and other drugs. Patients seeking treatment for HIV may present with a prior list of medications that they already take, and being aware of those medications&#x02019; potential interactions with nevirapine and the side effects of nevirapine can prevent unpredictable interactions. For example, nevirapine is a known inducer of cytochrome P450 enzymes, which means that this effect will impact any medication metabolized by this enzyme. Its dosing and administration will have to be adjusted accordingly for any given patient.</p>
        <p>Another significant interaction is that of nevirapine and methadone.<xref ref-type="bibr" rid="article-25853.r11">[11]</xref> Both nevirapine and methadone are metabolized by CYP2B6, which is a member of the human cytochrome P450 superfamily, but nevirapine is also an inducer of this enzyme. Due to nevirapine&#x02019;s ability to upregulate CYP2B6&#x02019;s metabolic function, methadone becomes metabolized significantly more quickly when administered simultaneously with nevirapine. This situation can pose a danger to the patient if the dosing of methadone is not adjusted accordingly, as someone utilizing it may metabolize it too quickly and then begin to exhibit withdrawal symptoms.<xref ref-type="bibr" rid="article-25853.r2">[2]</xref><xref ref-type="bibr" rid="article-25853.r12">[12]</xref></p>
      </sec>
      <sec id="article-25853.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>When discussing the toxicity of this drug, it is often secondary to the hepatic damage caused by the drug. There is currently no known antidote for nevirapine overdose.</p>
        <p>Another essential point to note regarding nevirapine toxicity is that of the currently known NNRTIs and protease inhibitors; it is the only one that has not shown any negative effect on lipids to date.<xref ref-type="bibr" rid="article-25853.r13">[13]</xref></p>
      </sec>
      <sec id="article-25853.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing patients taking nevirapine requires several factors, one of which is cohesive interprofessional teamwork. For treatment to be conducted smoothly and for the patient to receive the most significant benefit possible from it, every member of the interprofessional healthcare team, including clinicians (MDs, DOs, NPs, and PAs), nursing staff, and pharmacists, must be well informed about the treatment regimen and must actively work to ensure all members of the team are on the same page.<xref ref-type="bibr" rid="article-25853.r14">[14]</xref> &#x000a0;</p>
        <p>Another critical component is the meticulous and regular follow-up with said patients. Because of this medication&#x02019;s known potential for causing hepatotoxicity in those consuming it, patients&#x02019; liver functions must be monitored, especially in the beginning stages of treatment.<xref ref-type="bibr" rid="article-25853.r14">[14]</xref>&#x000a0;Again, interprofessional coordination and open communication are crucial elements&#x000a0;of effective patient monitoring for therapeutic effectiveness and safety.</p>
        <p>It is also important to note that the effectiveness of this medication relies heavily on patient compliance with taking the medication as prescribed. It is up to healthcare professionals to ensure patients are well informed about their responsibilities in ensuring they receive maximal improvement from the treatment. Healthcare professionals must further ensure that they view their patients as more than their illness and consider factors such as social support, finances, and mental health when monitoring patient adherence. If they note any signs of non-adherence (in patient interviews, failure to pick up prescriptions, etc.), they must immediately alert all interprofessional team members to implement interventions. All drugs require teamwork and open communication, but this is heightened for HIV therapy since non-adherence can invalidate entire classes of antiretroviral agents. Below are some examples of recommendations for methods to increase the success of HIV treatment in patients on antiviral therapy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Actively monitoring patient compliance with regular visits to see their healthcare professional.
<list list-type="bullet"><list-item><p>Beyond initially presenting for medical care, it is essential to ensure a patient follows up with their healthcare provider to determine treatment efficacy.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Patients should be asked for self-reported adherence regularly
<list list-type="bullet"><list-item><p>Although patients overestimate their adherence, self-reporting has a high predictive value.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>When monitoring patient adherence, checking refill data from the patient&#x02019;s respective pharmacy is recommended.
<list list-type="bullet"><list-item><p>Observational studies involving medical records and claims data confirm the validity of pharmacy refill data used to measure patient adherence to antiretroviral therapy. &#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Altering patient regimens from being complex to simpler once-daily regimens is a recommendation.
<list list-type="bullet"><list-item><p>Several studies have shown that switching patients to an easier regimen for taking medication improves their overall adherence.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Using technological devices to set reminders for taking medication is a recommendation.
<list list-type="bullet"><list-item><p>Studies have shown that setting routine alarms or reminders helps to increase adherence. Examples of some methods include receiving reminders via text message and receiving weekly check-ins from the clinic either via text message or phone call.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Working to concurrently provide antiretroviral therapy with screening, managing, and treating various mental illnesses is recommended.
<list list-type="bullet"><list-item><p>Randomized, controlled trials have shown that for patients with illnesses such as depression, providing them with cognitive-behavioral therapy and adherence counseling helps to improve their compliance with taking medication on time.<xref ref-type="bibr" rid="article-25853.r14">[14]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>With an interprofessional team approach that includes clinicians, specialists (particularly those infectious disease specialists who focus on HIV therapy), mid-level practitioners, nurses, and pharmacists, patient outcomes will be better, and adverse events will be minimized. [Level 5]</p>
      </sec>
      <sec id="article-25853.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25853">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25853/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25853">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25853.s11">
        <title>References</title>
        <ref id="article-25853.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirasawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Jun</month>
            <day>04</day>
            <volume>19</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">29867033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedrich</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Insights into CYP2B6-mediated drug-drug interactions.</article-title>
            <source>Acta Pharm Sin B</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>413</fpage>
            <page-range>413-425</page-range>
            <pub-id pub-id-type="pmid">27709010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells.</article-title>
            <source>Thorac Cancer</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>2243</fpage>
            <page-range>2243-2252</page-range>
            <pub-id pub-id-type="pmid">31631580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Molecular Network-Based Drug Prediction in Thyroid Cancer.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>11</day>
            <volume>20</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30641858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arts</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hazuda</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 antiretroviral drug therapy.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>a007161</fpage>
            <pub-id pub-id-type="pmid">22474613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Izzedine</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Launay-Vacher</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Aymard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Legrand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic of nevirapine in haemodialysis.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>192</fpage>
            <page-range>192-3</page-range>
            <pub-id pub-id-type="pmid">11209031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benedicto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fuster-Mart&#x000ed;nez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tosca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Esplugues</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Blas-Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Apostolova</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Jul</month>
            <day>04</day>
            <volume>10</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34359857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biswas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sawajan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rungrotmongkol</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sanachai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ershadian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sukasem</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>835136</fpage>
            <pub-id pub-id-type="pmid">35250581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Piedoux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Solas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Quaranta</surname>
                <given-names>S</given-names>
              </name>
              <collab>Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique</collab>
            </person-group>
            <article-title>[Evidence-based therapeutic drug monitoring for nevirapine].</article-title>
            <source>Therapie</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-95</page-range>
            <pub-id pub-id-type="pmid">21819802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Notter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bregenzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vernazza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kahlert</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?</article-title>
            <source>Swiss Med Wkly</source>
            <year>2019</year>
            <month>Apr</month>
            <day>22</day>
            <volume>149</volume>
            <fpage>w20053</fpage>
            <pub-id pub-id-type="pmid">31017649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bart</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brundage</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>227</volume>
            <fpage>109025</fpage>
            <pub-id pub-id-type="pmid">34482033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Back</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic drug interactions with nevirapine.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>34 Suppl 1</volume>
            <fpage>S8</fpage>
            <page-range>S8-14</page-range>
            <pub-id pub-id-type="pmid">14562853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamara</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ryom</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rickenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mocroft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Wit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Monforte</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Dabis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pradier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.</article-title>
            <source>Antivir Ther</source>
            <year>2016</year>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>495</fpage>
            <page-range>495-506</page-range>
            <pub-id pub-id-type="pmid">27114439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25853.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Amico</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Cargill</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orrell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Altice</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Bangsberg</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Beckwith</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Dowshen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stirratt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Remien</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Simoni</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nachega</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.</article-title>
            <source>Ann Intern Med</source>
            <year>2012</year>
            <month>Jun</month>
            <day>05</day>
            <volume>156</volume>
            <issue>11</issue>
            <fpage>817</fpage>
            <page-range>817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294</page-range>
            <pub-id pub-id-type="pmid">22393036</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
